Macrophages in the tumour microenvironment Flashcards

1
Q

What cells does the tumour microenvironment consist of?

A
The Tumour Microenvironment consists of many different cells: 
•Tumour cells
•Macrophages
•Monocytes
•T-cells
•BMDCs (Bone-marrow derived dendritic cells)
•Neutrophils
•Fibroblasts
•Stromal cells
•Endothelial cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Why would you target the tumour microenvironment?

A

Normal cells co-opted by tumour cells can promote cancer progression. Co-opted normal cells are genetically stable and so should not acquire mutations that contribute to therapeutic resistance. Cancer therapies could be enhanced by simultaneously targeting the tumour-promoting functions of cells in the microenvironment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How are macrophages attracted to tumour sites?

A

Macrophages are attracted to tumour sites by cytokines and chemokines. E.g. MCP-1, CSF-1 SDF-1, IL-4. They follow the gradient of these cytokines, the closer to the tumour, the higher the concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What the difference between tumour blood vessels and normal blood vessels?

A

Tumour blood vessels are very messy and curly, while normal blood vessels are straight and orderly.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the homeostatic functions of macrophages?

A

They have homeostatic functions:
•Tissue formation during development
•Phagocytosing or eating microorganisms, foreign particles and clearing dead or abnormal cells.
•Releasing chemical signals that recruit other types of immune cells to sites of injury/ infection.
•Patrolling and specialized tissue-specific macrophages.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How are macrophages replenished?

A

Macrophage are replenished by monocytes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the three theories on the embryological origin of macrophages

A

Model 1:
Labelling at d7.5 or 8.5 in Tie2-Cre mouse: hemogenic endothelial progeny cells are labelled
Tissue resident macrophages in the brain, liver and skin are foetal and adult macrophages arise from yolk sac progenitors, seeded before d9.5

Model 2:
Labelling at d7.5 or 8.5 in Runx1-Cre mouse: 2 waves of EMPs- primitive progenitors and definitive progenitors.
Tissue resident macrophages in the brain, the microglia, are separate populations.
The other tissue resident macrophages derive from a late EMP progenitor, which outcompete early
EMPs and transition through a foetal liver monocyte stage.

Model 3:
Using another tracing model, tissue resident macrophages have been shown to derive from a foetal haematopoietic stem cells, with the exception of brain microglia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What marker can you use to see the difference between microglia and tissue macrophages?

A

Microglia are F4/80 high and tissue macrophages are F4/80 low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Is the presence of a lot of macrophages a good sign in cancer?

A

More macrophages in cancer are a sign of worse prognosis in (almost) every cancer except colorectal cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Is every tissue resident macrophage the same in terms of transcriptional profile?

A

Tissue resident macrophages show diverse transcriptional profiles driven by tissue specific transcription factors. Environmental signals sculpt macrophage enhancer and gene expression. Transplant studies show tissue specific acquisition for newly arriving cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What do angiogenic macrophages express/secrete?

A

Angiogenic macrophages express/secrete VEGR1, CXCR4, TIE2, CtsB and CtsS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What do activated macrophages express/secrete? (inflammation)

A

Activated macrophages express/secrete IL-12, MHCII, iNOS and CD80

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What do immunosuppressive macrophages express/secrete? (immune regulation)

A

Immunosuppressive macrophages express/secrete arginase, IL-10 and CCL22

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What do perivascular and invasive macrophages express/secrete? (intravasion, invasion)

A

Perivascular and invasive macrophages express/secrete CtsB, CtsS, CtsZ and EGF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do cancer cells exit the tumour bulk?

A

Cancer cells exit the tumour bulk using “tracks” made by macrophages.

  1. Hypoxia recruits new vessels and allows immune influx of macrophages
  2. Macrophages release proteases to degrade ECM and basement membrane
  3. This allows for the influx of additional immune cells which pave the way from vessels to tumour
  4. Cells exposed to hypoxia change their behaviour (motile) in an attempt to find nutrients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the function of CCL2 in macrophages relating to cancer?

A

Tumour vessels are receptive to tumour cell entry and this sensing is orchestrated by macrophages. CCL2/CCR2 signaling in macrophages promotes their tumorigenic functions. Macrophages are recruited by CCL2 to favour metastasis.

17
Q

What parts of the (functions of the) tme can you target and with which drugs?

A
  • Tumour vasculature: bevacizumab (anti-VEGF-A), S-265610 (anti-CXCR2), Sunitinib (RTK inhibitor) and VEGF-Trap (decoy inhibitor).
  • Immune activation! (underlined in slide): ipilimumab (anti-CTLA-4), Nivolumab (anti-PD1R), Lambrolizumab (anti-PD-L1)
  • Repolarization and re-education! (underlined in slide): BLZ945 (anti-CSF-1R), CD40 mAb
  • Altered immune cell recruitment, expansion and depletion: PLX3397!(underlined in slide) (anti-CSF-1R and anti-KIT), S-265610 (anti-CXCR2), GW2580 (anti-CSF-1R), Trabectedin (chemotherapy)
  • Metastasis and/or outgrowth: MLN1202 (anti-CCR2)
18
Q

How can you target macrophages in solid tumours?

A

You can target macrophages in solid tumours by:

  • Targeting TEMs
  • Disrupting chemokine axes
  • Macrophage reprogramming
  • Targeting CSF-1R
  • Enhancing immune responses
19
Q

What is the influence of chemotherapy on macrophages in breast cancer?

A

Macrophages increase in breast cancer following chemotherapy

20
Q

How can you increase the response to paclitaxel?

A

Blocking macrophage recruitment or depletion of macrophages enhances response to paclitaxel

21
Q

What is the influence of macrophage on Taxol treatment?

A

Macrophages protect tumour cells from Taxol-induced cell death

22
Q

What is the principle of Taxol?

A
  1. Taxol-induced cancer cell death is consequent, rather than coincident, to mitotic arrest.
  2. Macrophage secreted factors reduce the duration of tumour cell mitotic arrest, promoting an earlier mitotic slippage
  3. Macrophage secreted factors suppress death in interphase after Taxol treatment
  4. MAPK pathway inhibition abrogates the chemoprotective effect of macrophages and improves the therapeutic response
23
Q

What does targeting macrophages with CSF-IR do for patients with diffuse-type giant cell tumours and regression of established gliomas?

A

Targeting macrophages with CSF-IR reduces tumour burden in patients with diffuse-type giant cell tumours and regression of established gliomas. CSF-IR affects several hallmarks of cancer:

  1. Tumour grade: complete histological response- already evident at day 3
  2. Proliferation: suppressed by up to 98% at day 3
  3. Apoptosis: increased by up to 17-fold at day 3
  4. Angiogenisis: vascular density decreased by >65% at day 7
24
Q

What is the influence of HDAC inhibitors on macrophages?

A

HDAC inhibitors mediate macrophage repolarisation/ reprogramming

25
Q

What does FGK45 do?

A

FGK45, a CD40 agonist targets macrophages in solid pancreatic tumours and additionally stimulates dendritic cells.

26
Q

What is the macrophage ontogeny in pancreatic tumours?

A

The gene expression profiles are very similar in embryonically and HSC-derived macrophages in the normal pancreas. Tissue-resident macrophages promote PDAC progression. Embryonically derived macrophages (30%) expand during tumour progression through in situ proliferation.
Embryonically derived macrophages have a distinct pro-fibrotic phenotype.
Embryonically derived macrophages further enhance their proliferative programs in comparison with their HSC-derived counterparts.

Macrophages of different origins have different impacts on tumour progression in PDACs